QUALITY OF LIFE IN DERMATOLOGY

Year 2019, Volume: 4 - Dermatology and Public Health Special Issue, 27 - 34, 11.03.2019

Seda Atay

https://doi.org/10.35232/estudamhsd.517027

Cited By: 1

Abstract

Quality of life is a term
that populations desire to reach in high levels. There are various types of
scales developed for measuring this concept. These measurement methods have
special attention for dermatological situations because these situations effect
lots of parameters including mental status and sociality. Some unfortunate
mental and emotional problems may cause skin diseases as pathogenesis. Also
people with some apparent skin diseases may avoid contacting with communities
because of negative reactions. All these effect and formalise the quality of
life. In this review, it is aimed to talk over scales about quality of life in
dermatological situations

Keywords

Dermatology, quality of life, evaluation

DERMATOLOJİDE YAŞAM KALİTESİ

Abstract

Yaşam
kalitesi, toplumların ulaşmayı amaçladığı en önemli genel hedeflerden birisi
olup günümüzde yaşam kalitesini ölçmek için pek çok yöntem kullanılmaktadır. Bu
ölçümler, dermatolojik durumlar için de özel bir öneme sahiptir çünkü
dermatolojik hastalıklar, kişilerin duygudurum ve sosyal yaşamını
etkilemektedir bununla birlikte psikojenik faktörler birçok deri hastalığının
patogenezinde rol oynamaktadır. Görülebilir bir cilt rahatsızlığı yaşayan
insanlar, etraflarındaki kişilerden olumsuz tepkiler alabilirler ve bunun
sonucunda sosyal ilişkilerden kaçınma davranışı sergileyebilirler. Tüm bunlar
bireylerin yaşam kalitesini şekillendiren birer unsurdur. Bu derlemede
dermatolojide kullanılan yaşam kalite ölçeklerine değinilmiştir.

Keywords

Dermatoloji, yaşam kalitesi, değerlendirme

References

• [1] Levine RJ. Quality of life assessments in clinical trials: an ethical perspective. In: Spilker B (editor). Quality of Life and Pharmacoeconomics in Clinical Trials. 2nd edition. Philedelphia, Lippincott-Raven Publishers, 1996; 51:489-495. [2] World Health Organization. The constitution of the WHO. WHO Chronicle, 1947; 1: 29.
• [3] Guyatt G, Walter S, Norman G: Measuring change over time: assessing the usefulness of evaluative instruments. J Chronic Dis 1987; 40: 171–178.
• [4] Hughes JE, Barraclough BM, Hamblin L, White JE. Psychiatric symptoms in dermatology patients. British Journal of Psychiatry. 1983;143:51-54.
• [5] Dalgard FJ, Gieler U, Tomas-Aragones L, Lien L, Poot F, Jemec GB, Misery L, Szabo C, Linder D, Sampogna F, Evers AW. The psychological burden of skin diseases: a cross-sectional multicenter study among dermatological out-patients in 13 European countries., Journal of Investigative Dermatology. 2015; 135:984-999.
• [6] Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994 May;19(3):210-216.
• [7] Montgomery K, Norman P, Messenger AG, Thompson AR. The importance of mindfulness in psychosocial distress and quality of life in dermatology. Br J Dermatol. 2016 Nov;175(5):930-936.
• [8] Both H, Essink-Bot ML, Busschbach J, Nijsten T: Critical review of generic and dermatology- specific health-related quality of life instruments. J Invest Dermatol 2007; 127: 2726– 2739.
• [9] Finlay, AY., Khan, GK., Luscombe, DK., Salek, MS. Validation of Sickness Impact Profile and Psoriasis Disability Index in Psoriasis. British Journal of Dermatology. 1990; 123: 751-756.
• [10] Williams, S J. 1994. Measuring Functional Limitations and sickness Impact: A critical Review of the FLP and SIP. In: Jenkinson, C. (ed). 1994. Measuring Health Status and Medical Outcomes. Social research Today series No. 3. UCL Press.
• [11] Prins M, Krabbe PF, Swinkels QO, de Boo T, van de Kerkhof PC, van der Valk PG. The effect of treatment on quality of life in psoriasis patients. Acta Derm Venereol 2005;85:304–310.
• [12] Wall AR, Poyner TF, Menday AP. A comparison of treatment with dithranol and calcipotriol on the clinical severity and quality of life in patients with psoriasis. Br J Dermatol 1998; 139:1005–1011.
• [13] de Korte J, Mombers FM, Sprangers MA, Bos JD. The suitability of quality-of-life questionnaires for psoriasis research: a systematic literature review. Arch Dermatol 2002; 138:1221–1227.
• [14] Köse O, Gür AR: Dermatolojide yaşam kalitesi ve ölçümü. T Klin Dermatoloji 2000;10:270-274.
• [15] Ware J Jr, Kosinski M, Keller SD. A 12-item short-form health survey: construction of scales and preliminary tests of reliability and validity. Med Care 1996;34:220–233.
• [16] Koçyiğit H, Aydemir Ö, Ölmez N ve ark. SF-36’nın Türkçe için güvenilirliği ve geçerliliği. İlaç ve tedavi 1999; 12:102-106.
• [17] Abeni D, Picardi A, Pasquini P, Melchi CF, Chren MM. Further evidence of the validity and reliability of the Skindex-29: an Italian study on 2,242 dermatological outpatients. Dermatology 2002;204: 43–49.
• [18] Chren MM, Lasek RJ, Flocke SA, Zyzanski SJ. Improved discriminative and evaluative capability of a refined version of Skindex, a qualityof- life instrument for patients with skin diseases. Arch Dermatol 1997;133:1433–1440. [19] Lewis V, Finlay AY. 10 years experience of the Dermatology Life Quality Index (DLQI). J Investig Dermatol Symp Proc 2004;9:169–180.
• [20] Bingefors K, Lindberg M, Isacson D (2002) Self-reported dermatological problems and use of prescribed topical drugs correlate with decreased quality of life: an epidemiological survey. Br J Dermatol 2002; 147: 285–290.
• [21] Reich K, Nestle FO, Papp K, Ortonne JP, Wu Y, Bala M et al. Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial. Br J Dermatol 2006;154:1161–1168. [22] Wallenhammar LM, Nyfjall M, Lindberg M, Meding B. Health-related quality of life and hand eczema—a comparison of two instruments, including factor analysis. J Invest Dermatol 2004;122:1381–1389.
• [23] Hunt SM, McKenna SP, McEwen J, Williams J, Papp E. The Nottingham Health Profile: subjective health status and medical consultations. Soc Sci Med A. 1981 May;15(3 Pt 1):221-229.
• [24] WHOQOL Group. Development of the World Health Organization WHOQOL-BREF quality of life assessment. Psychol Med 1998; 28:551–558.
• [25] Finlay AY. Quality of Life Indices. Indian J Dermatol Venereol Leprol 2004; 70: 143-148.
• [26] Morgan M, McCreedy R, Simpson J: Dermatology quality of life scales- a measure of impact of skin diseases. Br J Dermatol 1997;136:202-206.
• [27] Oztürkcan S, Ermertcan AT, Eser E, Sahin MT. Cross validation of the Turkish version of dermatology life quality index. Int J Dermatol 2006; 45: 1300-1307.
• [28] Koku AAE, Saraçoğlu ZN, Sabuncu İ, Chren MM, Tozun M. Validity and reliability of the Turkish version of the Skindex-16. Turkderm - Arch Turk Dermatol Venerology 2016;50:109-113.
• [29] Gurel MS, Yanik M, Simsek Z, Kati M, Karaman A. Quality of life instrument for Turkish people with skin diseases. Int J Dermatol 2005; 44(11): 933-938. [30] Chen SC, Yeung J, Chren MM. Scalpdex: a quality-of-life instrument for scalp dermatitis. Arch Dermatol 2002;138(6): 803-807. [31] Fischer TW, Schmidt S, Strauss B, Elsner P. Hairdex: a tool for evaluation of disease-specific quality of life in patients with hair diseases. Hautarzt 2001;52(3):219- 227.
• [32] Anderson RT, Rajagopalan R, Winston S: Development and validation of a quality of life instrument for cutaneous diseases. J Am Acad Dermatol 1997;37:41-50.
• [33] Bilaç C, Öztürkcan S. Dermatolojide yaşam kalitesi. Sağlıkta birikim 2006; 1: 48-58. [34] Motley RJ, Finlay AY: How much disability is caused by acne? Clin Exp Dermatol 1989;14:194-198.
• [35] Motley RJ, Finlay AY: Practical use of a disability index in the routine management of acne. Clin Exp Dermatol 1992;17:1-3. [36] Demircay Z, Senol A, Seckin D, Demir F. [Reliability of Turkish version of acne quality of life scale in patients with acne vulgaris]. Turkderm 2006;40(2):94-97.
• [37] Finlay AY, Kelly SE. Psoriasis--an index of disability. Clin Exp Dermatol 1987; 12(1): 8-11.
• [38] Mease PJ, Menter MA. Quality-of-life issues in psoriasis and psoriatic arthritis: outcome measures and therapies from a dermatological perspective. J Am Acad Dermatol 2006; 54(4): 685-704.
• [39] Rehal B, Armstrong AW. Health outcome measures in atopic dermatitis: a systematic review of trends in disease severity and quality-of-life instruments 1985-2010. PLoS One. 2011 Apr 13;6(4):e17520.
• [40] Onsun N. Atopik dermatit ve yaşam kalitesi. Turkderm 1998; 32(1).
• [41] Whalley D, McKenna SP, Dewar AL, Erdman RA, Kohlmann T, Niero M, Cook SA, Crickx B, Herdman MJ, Frech F, Van Assche D. A new instrument for assessing quality of life in atopic dermatitis: international development of the Quality of Life Index, for Atopic Dermatitis (QoLIAD). Br J Dermatol 2004; 150(2): 274-283.
• [42] Baiardini I, Pasquali M, Braido F, Fumagalli F, Guerra L, Compalati E, Braga M, Lombardi C, Fassio O, Canonica GW. A new tool to evaluate the impact of chronic urticaria quality of life questionnaire (CU-QoL). Allergy 2005; 60(8): 1073-1078.
• [43] Dolte KS, Girman CJ, Hartmaier S, Roberts J, Bergfeld W, Waldstreicher J. Development of a health-related quality of life questionnaire for women with androgenetic alopecia. Clin Exp Dermatol 2000; 25(8): 637-642.
• [44] Balkrishnan R, McMichael AJ, Camacho FT, Saltzberg F, Housman TS, Grummer S, Feldman SR, Chren MM. Development and validation of a health-related quality of life instrument for women with melasma. Br J Dermatol 2003; 149(3): 572-577.
• [45] Warshaw EM, Foster JK, Cham PM, Grill JP, Chen SC. NailQoL: a quality-of-life instrument for onychomycosis. Int J Dermatol 2007; 46(12): 1279-1286.